The Advances in Gastrointestinal Cancer Resource Centre Introduction
The Advances in Gastrointestinal Cancer Resource Centre is dedicated to disseminating cutting edge data to practising healthcare professionals. Our aim is to provide clinically relevant information in order to enhance the caregivers' ability to provide optimal care for their gastrointestinal (GI) cancer patients. We will offer journal articles, patient case reports, interviews, and roundtable discussions with experts, with additional content aimed at expanding your expertise in the multidisciplinary field of GI cancer. This freely available resource, hosted by European Journal of Cancer and Clinical Colorectal Cancer, will function as a hub of information for healthcare professionals. 

Our initial focus for Advances in Gastrointestinal Cancer will centre on gastric cancer, with future expansion to all GI malignancies. New content will be posted monthly, and the Editors encourage you to visit the site regularly to stay abreast of recent scientific developments in GI cancers. Please subscribe to our eAlert to ensure you are informed of all new content as it is published on this platform.

Articles of the Month

Both articles are selected and commented by Dr Ian Chau:

This month in gastric cancer the result of the KEYNOTE 012 study were published in the Lancet Oncology.  This is the first published trial of anti-PD-1 therapy in gastric cancer and provides important proof of concept for the efficacy of these exciting new drugs for gastric cancer patients. In KEYNOTE 012 patients were screened using an immunohistochemistry assay for PD-L1 positivity. Approximately 40% of patients screened were PD-L1 positive and thirty nine patients were treated with the anti-PD-1 antibody pembrolizumab on the trial. Eight patients responded to treatment (22% ORR) and responses were durable with a median duration of response of forty weeks, in fact, half of responding patients had not progressed at the time of study reporting. Pembrolizumab was well tolerated, no patient was withdrawn from treatment due to immune mediated toxicity.   

Large randomised trials are ongoing to assess the benefit of anti-PD-1 therapies such as pembrolizumab and nivolumab in patients with gastric cancer. A key questions which remains to be answered is whether PD-L1 positivity is a sensitive and specific biomarker to predict response to such therapies. Additionally, it will be important to address the issue of heterogeneity of biomarker expression which is associated with gastric cancer in order to accurately select patients for treatment.

Latest Articles


Interviews from The European Cancer Congress, Vienna, September, 2015


Editors

Professor Florian Lordick

University Hospital Leipzig, Leipzig, Germany

Dr Ian Chau

Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK

Professor David Cunningham

Director of the Royal Marsden/Institute of Cancer Research NIHR Biomedical Research Centre and Director of Clinical Research

Dr James J. Lee

Division of Medical Oncology and Hematology, UPMC Cancer Centre, Pittsburgh, PA, USA

Dr Elizabeth Smyth

University College Dublin, Dublin, Ireland

Search this site

Search form

E-Alert

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Featured Content

New Book Content


  • ECC Symposium: The why, the which, and the how of targeting angiogenesis in GI malignancies

    Official Sponsored Satellite Symposium at European Cancer Congress 2015 - Monday 28 September 2015

This online Resource Centre has been sponsored by Lilly Oncology

Note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subject to an independent editorial review.

Share

Upcoming events